Another report from a GSDIb patient with bowel disease treated with G-CSF and continuous gastric deep feeding showed events of asymptomatic mild hypoglycemia < 3.3 mmol/L (range 2.6–3.3) measured by flash glucose monitoring during the first week of treatment and promptly corrected by oral glucose administration (24). This evidence concerns the gene CSF3 and Hypoglycemia.